Alan B. Lancz & Associates’s Sanofi SNY Stock Holding History

Alan B. Lancz & Associates’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,000	Closed	-$242K	–	137
2025 Q4	$242K	Hold	5,000	–	–	0.21%	116
2025 Q3	$236K	Sell	5,000 -250	-5%	-$12.1K	0.21%	120
2025 Q2	$254K	Hold	5,250	–	–	0.25%	109
2025 Q1	$291K	Hold	5,250	–	–	0.31%	90
2024 Q4	$253K	Sell	5,250 -800	-13%	-$40.7K	0.26%	101
2024 Q3	$349K	Sell	6,050 -250	-4%	-$13.5K	0.32%	82
2024 Q2	$306K	Buy	+6,300	New	+$304K	0.3%	91
2023 Q4	$324K	Sell	6,510 -175	-3%	-$8.56K	0.34%	86
2023 Q3	$359K	Sell	6,685 -290	-4%	-$15.5K	0.41%	75
2023 Q2	$376K	Hold	6,975	–	–	0.4%	82
2023 Q1	$380K	Buy	6,975 +10	+0.1%	+$486	0.39%	82
2022 Q4	$343K	Sell	6,965 -400	-5%	-$17.6K	0.35%	91
2022 Q3	$280K	Hold	7,365	–	–	0.33%	92
2022 Q2	$366K	Sell	7,365 -400	-5%	-$21.2K	0.36%	82
2022 Q1	$399K	Hold	7,765	–	–	0.35%	83
2021 Q4	$389K	Buy	+7,765	New	+$384K	0.34%	84

Other funds holding SNY

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Alan B. Lancz & Associates's SNY Position: Q1 2026 in Review

Alan B. Lancz & Associates sold out of Sanofi (SNY) in Q1 2026, closing a stake of 5,000 shares — an estimated $242K sold.

Alan B. Lancz & Associates first reported a position in SNY in Q4 2021 and held it in 16 quarters. The position peaked at $399K in Q1 2022. 738 funds tracked by Wall St. Rank hold SNY as of Q1 2026.

Alan B. Lancz & Associates reported no remaining Sanofi position as of Q1 2026 after selling out during the quarter.
Alan B. Lancz & Associates sold 5,000 Sanofi shares in Q1 2026, an estimated $242K.
Alan B. Lancz & Associates first reported a position in Sanofi in Q4 2021 and held it in 16 quarters.
Alan B. Lancz & Associates's Sanofi position peaked at $399K in Q1 2022.
738 funds tracked by Wall St. Rank held Sanofi as of Q1 2026.

Based on Alan B. Lancz & Associates's 13F filing for Q1 2026, filed 5 May 2026.